Nebenwirkungen · Taltz
Taltz 40 mg solution for injection in pre-filled syringe Taltz 80 mg solution for injection in pre-filled syringe · Abschnitt 4.8 · PDF-Seite 9
HOS-133063 · Präparat HOS-097358
In psoriatic arthritis patients treated with Taltz at the recommended dosing regimen up to 52 weeks, approximately 11% developed anti-drug antibodies, the majority of which were low titre, and approximately 8% had confirmed neutralising antibodies. No apparent association between the presence of neutralising antibodies and impact on drug concentration or efficacy was observed.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-04-23T15:10:00Z · SHA-256 f449380f0849b33ad619f5ae5676924bf717d85b4fc30ce625002744eb8359ab · Passage caaeee702a4a310d720a0409d70e90b7b04ba2312056b4dbbf3b4d20549743f0 · Zeichen 7768–8147 im Abschnitt